BiomX Inc. (PHGE)
| Market Cap | 10.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.06M |
| Shares Out | 26.18M |
| EPS (ttm) | -2.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,478 |
| Open | 0.4010 |
| Previous Close | 0.4100 |
| Day's Range | 0.4010 - 0.4245 |
| 52-Week Range | 0.3400 - 3.5920 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 15.00 (+3,514.46%) |
| Earnings Date | Aug 13, 2025 |
About PHGE
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clini... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for PHGE stock is "Strong Buy" and the 12-month stock price target is $15.0.
News
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, upda...
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phas...
BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript
BiomX Inc. (NYSE:PHGE) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wain...
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO)
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that...
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conferenc...
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX Announces a Mandatory Unit Separation
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that ...
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units...
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & C...
BiomX Inc. Announces 1-for-10 Reverse Stock Split
GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
Top 3 Health Care Stocks That May Explode In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
GAITHERSBURG, Md., July 29, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that t...
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered ...